Related Experiment Video
Updated: Jun 2, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Preclinical studies of gossypol in prostate carcinoma
1WAYNE STATE UNIV,SCH MED,DIV HEMATOL & ONCOL,DETROIT,MI 48201. COLUMBIA PRESBYTERIAN MED CTR,DIV MED ONCOL,NEW YORK,NY 10032. UNIV MICHIGAN,SCH MED,DIV HEMATOL & ONCOL,ANN ARBOR,MI 48109.
Abstract:
Hormone refractory prostate cancer remains an incurable disease and the discovery of newer agents with higher cytotoxic activity is required. Gossypol is a phenolic compound isolated from cottonseed oil which has been shown to have anti-spermatogenic effects. In in vitro studies, gossypol appears to inhibit the growth of rat prostate cancer cell line MAT-LyLu and human prostate adenocarcinoma cell lines PC-3, LNCaP and DU-145. In vive, gossypol appeared to inhibit tumor growth of subcutaneously implanted MAT-LyLu cells in Copenhagen rats. Gossypol may be an active agent for the treatment of hormone refractory metastatic prostate cancer.
Insights
Gossypol, a compound from cottonseed, shows promise for treating hormone refractory prostate cancer. Studies indicate it inhibits cancer cell growth in vitro and tumor development in vivo.
Area of Science:
- Oncology
- Pharmacology
Background:
- Hormone refractory prostate cancer is currently incurable.
- There is a need for novel therapeutic agents with enhanced cytotoxic activity.
Purpose of the Study:
- To investigate the potential of gossypol as a treatment for hormone refractory metastatic prostate cancer.
Main Methods:
- In vitro studies using rat (MAT-LyLu) and human (PC-3, LNCaP, DU-145) prostate cancer cell lines.
- In vivo studies involving subcutaneously implanted MAT-LyLu cells in Copenhagen rats.
Main Results:
- Gossypol demonstrated inhibition of prostate cancer cell line growth in vitro.
- Gossypol inhibited tumor growth in vivo in a rat model.
Conclusions:
- Gossypol exhibits cytotoxic and anti-tumor effects against prostate cancer models.
- Gossypol may represent a potential therapeutic agent for hormone refractory metastatic prostate cancer.
